Expert Thoughts on Studies of Interest Presented at the 2022 ESGO Annual Meeting on Gynecologic Cancers

11/29/22 • 27 min

In this episode, Prof Isabelle Ray Coquard, MD, PhD, and Ignace Vergote, MD, PhD, share their thoughts on key studies of interested presented at the 2022 ESGO annual meeting in Berlin, Germany, including:

• Phase III CALLA trial of durvalumab combined with and following chemoradiotherapy in locally advanced cervical cancer

• Geneva HRD test: validation of samples from PAOLA-1 dataset using Geneva laboratory–developed test

• Validation of NOGGO-GIS HRD assay using samples from the PAOLA-1 trial

• Survival results from phase III ARIEL3: maintenance rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer

Presenters:

Isabelle Ray-Coquard, MD, PhD
Professor of Department of Medical Oncology
Clinical Science Institute of the Léon Bérard Center
Lyon, France

Ignace Vergote, MD, PhD
Professor Em. of Department of Obstetrics and Gynecologic Oncology
University Hospitals Leuven
Leuven, Belgium

Content supported by educational grants from AstraZeneca, GlaxoSmithKline, Karyopharm Therapeutics, and Merck Sharp & Dohme Corp.

Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries:
https://bit.ly/3SSSqpN

• Phase III CALLA trial of durvalumab combined with and following chemoradiotherapy in locally advanced cervical cancer

• Geneva HRD test: validation of samples from PAOLA-1 dataset using Geneva laboratory–developed test

• Validation of NOGGO-GIS HRD assay using samples from the PAOLA-1 trial

• Survival results from phase III ARIEL3: maintenance rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer

Presenters:

Isabelle Ray-Coquard, MD, PhD
Professor of Department of Medical Oncology
Clinical Science Institute of the Léon Bérard Center
Lyon, France

Ignace Vergote, MD, PhD
Professor Em. of Department of Obstetrics and Gynecologic Oncology
University Hospitals Leuven
Leuven, Belgium

Content supported by educational grants from AstraZeneca, GlaxoSmithKline, Karyopharm Therapeutics, and Merck Sharp & Dohme Corp.

Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries:
https://bit.ly/3SSSqpN

Previous Episode

Evolving Role of BTK Inhibitors in CLL: Experts Answer Your Questions

In this episode, Farrukh T. Awan, MD, and Nicole Lamanna, MD, answer questions from an audience of healthcare professionals on topics related to the use of BTK inhibitors for the management of chronic lymphocytic leukemia (CLL). The topics covered include:

Whether it is justifiable to use chlorambucil plus obinutuzumab as a control arm in a registrational trial today
Relevance of overall response rate vs progression-free survival for BTK inhibitor therapy
Approval of ibrutinib/venetoclax combination therapy for patients with CLL
Key differences between zanubrutinib and acalabrutinib in the treatment of patients with CLL
How to transition/overlap next therapy in patients with CLL with progression while receiving a BTK inhibitor

Faculty:
Farrukh T. Awan, MD
Associate Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

Nicole Lamanna, MD
Associate Professor
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York

Link to the complete program, including downloadable slidesets and an on-demand webcast:
https://bit.ly/3EjvSKm

Next Episode

undefined - A Patient’s Perspective on Effective Communication With the Healthcare Team: My Journey With High-Risk HR-Positive/HER2-Negative Early Breast Cancer

A Patient’s Perspective on Effective Communication With the Healthcare Team: My Journey With High-Risk HR-Positive/HER2-Negative Early Breast Cancer

In this episode, Zoe Lanham, a woman with high-risk hormone receptor–positive/HER2-negative early breast cancer, discusses the importance of effective communication between patients and their healthcare team, drawing on her personal experience.

Presenter:

Zoe Lanham
Patient

Link to full program:
https://bit.ly/3Fukjzk